Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Shigellosis vaccine (Primary) ; DTaP vaccine; Meningococcal vaccine groups A C Y W-135 conjugate; Rabies vaccine
Indications Shigella infections
Focus Adverse reactions; First in man; Pharmacodynamics
Sponsors LimmaTech Biologics

22 Feb 2024 According to a LimmaTech Biologics media release, the interim from this Phase I/II data were previously presented at the BactiVac 4th Annual Network Meeting 2023 held in Birmingham, UK.
22 Feb 2024 According to a LimmaTech Biologics media release, topline results from this completed Phase I/II are expected in the first half of 2024.
22 Feb 2024 Positive interim from this trial presented in a LimmaTech Biologics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com